Evidence map›Paper›PMID 40183572›Full record

ArticleCancer science2025

Evans Blue Acts as a Selective Inhibitor of CaMKII-α to Impede the Progression of TCL Identified by HTS.

Jianru Tian, Aiqin Zhang, Lansong Li, Hong Liu, Hui Jiang, Ruqi Liang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jianru TianCollege of Textile Engineering, Taiyuan University of Technology, Taiyuan, China.ORCID https://orcid.org/0009-0001-0862-4972
Aiqin ZhangCollege of Textile Engineering, Taiyuan University of Technology, Taiyuan, China.
Lansong LiCollege of Chemistry and Chemical Engineering, Taiyuan University of Technology, Taiyuan, China.
Hong LiuCollege of Chemistry and Chemical Engineering, Taiyuan University of Technology, Taiyuan, China.
Hui JiangCollege of Chemistry and Chemical Engineering, Taiyuan University of Technology, Taiyuan, China.
Ruqi LiangCollege of Chemistry and Chemical Engineering, Taiyuan University of Technology, Taiyuan, China.

Funding

National Science Foundation of Shanxi Province 202303021212068Research Start-up Foundation of Taiyuan University of Technology RY2400000585Science and Technology Innovation Project of Universities in Shanxi Province RD2300004063
6 · The paper itself

Abstract

T-cell lymphoma (TCL) poses a significant challenge in clinical oncology, characterized by its aggressive behavior and resistance to conventional therapies. Despite considerable research efforts, the prognosis for TCL patients remains poor, primarily due to the lack of effective therapeutic strategies that can inhibit tumor progression and metastasis. In this study, we identified CaMKII-α as a potential therapeutic target for TCL. To explore its role in TCL pathogenesis, we investigated its effects on TCL cell lines. Protein expression levels within the PI3K-AKT signaling pathway were assessed using western blot analysis. Through siRNA-mediated gene silencing, we downregulated CaMKII-α expression and monitored TCL cell proliferation. Furthermore, we identified Evans Blue (IC

Indexed as

Antineoplastic AgentsCalcium-Calmodulin-Dependent Protein Kinase Type 2Evans BlueLymphoma, T-CellProtein Kinase InhibitorsAnimalsCell Line, TumorCell ProliferationDisease ProgressionHumansMicePhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, Small InterferingSignal TransductionAntineoplastic AgentsCalcium-Calmodulin-Dependent Protein Kinase Type 2Evans BluePhosphatidylinositol 3-KinasesProtein Kinase InhibitorsProto-Oncogene Proteins c-aktRNA, Small InterferingCaMKII‐αEvans bluehigh throughput screeningselective small‐molecule inhibitorT‐cell lymphoma

Identifiers

PMID40183572
PMCPMC12210032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.